The detection of cancer at an early stage while it is curable by surgical resection is widely
believed to be one of the most effective strategies for reducing cancer mortality. Hence, the …

Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

PCR-based techniques routinely employed for the detection of mutated linear DNA
molecules, including circulating tumor DNA (ctDNA), require large nucleotide sections on …

Introduction Breast cancer causes the most cancer-related death in women and is the
costliest cancer in the US regarding medical service and prescription drug expenses. Breast …

Illumina is the leading sequencing platform in the next-generation sequencing (NGS) market
globally. In recent years, MGI Tech has presented a series of new sequencers, including …

Tumor-specific, circulating cell-free DNA (cfDNA) in liquid biopsy test is a novel promising
biomarker in the advancement of cancer management, including early diagnosis, screening …

The excellent specificity and selectivity of Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR)/associated nuclease (Cas) is determined by CRISPR RNA's …

Abstract Purpose: Cell-free DNA (cfDNA) analysis is a powerful tool for noninvasively
predicting patient outcomes. We analyzed the size distribution of cfDNA and assessed its …

To save lives from cancer, it is very crucial to diagnose it at its early stages. One solution to
early diagnosis lies in the identification of the cancer driver genes and their mutations. Such …

Background An exploratory, proof-of-concept, liquid biopsy addendum to examine
biomarkers within cell-free DNA (cfDNA) in the RELAY phase 3, randomized, double-blind …